Income Statement Matricelf Ltd

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 10:24:03 2026-09-10 EDT			5-day change	1st Jan Change
266.50 ^ILa	-0.67%		-11.08%	-51.62%

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI

082f32a14ee7.i20JTZH6HQEOxrm1EmH_GAaoRjCEqac3BNsDUVf36X8.7SdmeP_IS21n84vdIy3GXFWZcHHbxuJcSqlVYRSlpQXCDj8ppsh0W2ig2g

Published financial data: MATRICELF LTD

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (ILS)	2022 (ILS)	2023 (ILS)	2024 (ILS)	2025 (ILS)
Cost of Goods Sold, Total	-	197K	255K	272K	578K
Gross Profit	-	-197K	-255K	-272K	-578K
Selling General & Admin Expenses, Total	7.91M	3.5M	4.12M	4.4M	5.44M
R&D Expenses	8.2M	8.89M	10.33M	11.44M	12.31M
Other Operating Expenses	-42K	-10K	-	-	-
Other Operating Expenses, Total	16.07M	12.39M	14.46M	15.84M	17.75M
Operating Income	-16.07M	-12.59M	-14.71M	-16.11M	-18.33M
Interest Expense, Total	-145K	-147K	-139K	-188K	-144K
Interest And Investment Income	12K	239K	1.08M	731K	403K
Net Interest Expenses	-133K	92K	936K	543K	259K
Currency Exchange Gains (Loss)	1K	24K	-29K	-2K	-182K
Other Non Operating Income (Expenses)	-136K	-16K	-8K	-10K	-9.57M
EBT, Excl. Unusual Items	-16.34M	-12.49M	-13.82M	-15.58M	-27.82M
Gain (Loss) On Sale Of Assets	-	-	-3K	-	-
Other Unusual Items	-	-	-13K	-	-
EBT, Incl. Unusual Items	-16.34M	-12.49M	-13.83M	-15.58M	-27.82M
Income Tax Expense	-	-	-	-	-
Earnings From Continuing Operations	-16.34M	-12.49M	-13.83M	-15.58M	-27.82M
Net Income to Company	-16.34M	-12.49M	-13.83M	-15.58M	-27.82M
Net Income - (IS)	-16.34M	-12.49M	-13.83M	-15.58M	-27.82M
Preferred Dividend and Other Adjustments	-	-	190K	523K	43K
Net Income to Common Incl Extra Items	-16.34M	-12.49M	-14.02M	-16.1M	-27.86M
Net Income to Common Excl. Extra Items	-16.34M	-12.49M	-14.02M	-16.1M	-27.86M
Per Share Items
Net EPS - Basic	-1.88	-0.95	-0.89	-0.98	-1.51
Basic EPS - Continuing Operations	-1.88	-0.95	-0.89	-0.98	-1.51
Basic Weighted Average Shares Outstanding	8.7M	13.12M	15.77M	16.41M	18.45M
Net EPS - Diluted	-1.88	-0.95	-0.89	-0.98	-1.51
Diluted EPS - Continuing Operations	-1.88	-0.95	-0.89	-0.98	-1.51
Diluted Weighted Average Shares Outstanding	8.7M	13.12M	15.77M	16.41M	18.45M
Normalized Basic EPS	-1.17	-0.59	-0.55	-0.59	-0.94
Normalized Diluted EPS	-1.17	-0.59	-0.55	-0.59	-0.94
Supplemental Items
EBITDA	-15.82M	-12.13M	-14.2M	-15.52M	-17.72M
EBITA	-16.07M	-12.59M	-14.71M	-16.11M	-18.33M
EBIT	-16.07M	-12.59M	-14.71M	-16.11M	-18.33M
Effective Tax Rate - (Ratio)	-	-	-	-	-
Normalized Net Income	-10.21M	-7.8M	-8.63M	-9.74M	-17.39M
Interest on Long-Term Debt	138K	147K	139K	188K	144K
Supplemental Operating Expense Items
General and Administrative Expenses	7.91M	3.5M	4.12M	4.4M	5.44M
Research And Development Expense From Footnotes	8.2M	9.09M	10.59M	11.71M	12.88M
Maintenance & Repair Expenses, Total	-	197K	255K	272K	578K
Stock-Based Comp., R&D Exp. (Total)	3.18M	1.42M	2.38M	2.4M	293K
Stock-Based Comp., G&A Exp. (Total)	5.7M	1.24M	1.26M	1.48M	1.56M
Stock-Based Comp., Other (Total)	131K	-	141K	-	-
Total Stock-Based Compensation	9.01M	2.66M	3.78M	3.88M	1.85M

Fiscal Period: December	2021 (ILS)	2022 (ILS)	2023 (ILS)	2024 (ILS)	2025 (ILS)
Assets
Cash And Equivalents	22.43M	-	2.49M	86K	17.42M
Short Term Investments	-	-	21.09M	11.85M	3.52M
Total Cash And Short Term Investments	22.43M	-	23.58M	11.94M	20.94M
Other Receivables	157K	-	187K	443K	553K
Total Receivables	157K	-	187K	443K	553K
Prepaid Expenses	119K	-	92K	169K	348K
Other Current Assets, Total	-	-	67K	96K	871K
Total Current Assets	22.7M	-	23.93M	12.64M	22.71M
Gross Property Plant And Equipment	3.92M	-	5.74M	6.16M	6.7M
Accumulated Depreciation	-264K	-	-2.17M	-3.16M	-4.17M
Net Property Plant And Equipment	3.66M	-	3.57M	3M	2.54M
Other Intangibles, Total	2.44M	-	2.61M	2.61M	2.61M
Other Long-Term Assets, Total	105K	-	95K	96K	-
Total Assets	28.9M	-	30.2M	18.35M	27.86M
Liabilities
Accounts Payable, Total	89K	-	633K	709K	585K
Accrued Expenses, Total	1.04M	-	1.28M	1.22M	2.34M
Short-term Borrowings	-	-	-	-	-
Current Portion of Leases	299K	-	367K	457K	421K
Other Current Liabilities	-	-	-	-1K	14.05M
Total Current Liabilities	1.43M	-	2.28M	2.39M	17.4M
Long-Term Leases	1.24M	-	1.12M	799K	379K
Total Liabilities	2.67M	-	3.4M	3.19M	17.78M
Common Stock, Total	120K	-	162K	162K	276K
Additional Paid In Capital	47.89M	-	74.92M	79.39M	102M
Retained Earnings	-21.78M	-	-48.28M	-64.39M	-92.25M
Total Common Equity	26.23M	-	26.8M	15.17M	10.08M
Total Equity	26.23M	-	26.8M	15.17M	10.08M
Total Liabilities And Equity	28.9M	-	30.2M	18.35M	27.86M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	12.06M	13.12M	15.91M	16.16M	27.58M
ECS Total Common Shares Outstanding	12.06M	13.12M	15.91M	16.16M	27.58M
Book Value / Share	2.17	-	1.68	0.94	0.37
Tangible Book Value	23.79M	-	24.19M	12.55M	7.47M
Tangible Book Value Per Share	1.97	-	1.52	0.78	0.27
Total Debt	1.54M	-	1.49M	1.26M	800K
Net Debt	-20.88M	-	-22.09M	-10.68M	-20.14M
Account Code - Inventory Valuation	3	-	-	3	3
Machinery, Total	1.23M	-	2.19M	2.43M	3.03M
Full Time Employees	11	-	-	12	15

Fiscal Period: December	2021 (ILS)	2022 (ILS)	2023 (ILS)	2024 (ILS)	2025 (ILS)
Net Income	-16.34M	-12.49M	-13.83M	-15.58M	-27.82M
Depreciation & Amortization - CF	554K	811K	851K	988K	1M
Depreciation & Amortization, Total	554K	811K	851K	988K	1M
(Gain) Loss From Sale Of Asset	1K	-	3K	-	56K
Stock-Based Compensation (CF)	9.01M	2.28M	3.78M	3.52M	1.85M
Other Operating Activities, Total	272K	-14K	-939K	-364K	9.65M
Change In Accounts Receivable	-70K	-30K	-	-256K	-110K
Change In Accounts Payable	-95K	378K	166K	75K	-367K
Change in Other Net Operating Assets	47K	759K	-518K	-131K	942K
Cash from Operations	-6.62M	-8.3M	-10.49M	-11.75M	-14.8M
Capital Expenditure	-2.4M	-428K	-616K	-243K	-597K
Sale of Property, Plant, and Equipment	7K	-	20K	-	-
Sale (Purchase) of Intangible assets	-	-174K	-	-	-
Investment in Marketable and Equity Securities, Total	-	-31M	10.4M	9.14M	8.33M
Other Investing Activities, Total	18K	-64K	722K	802K	-570K
Cash from Investing	-2.38M	-31.66M	10.53M	9.7M	7.16M
Short Term Debt Issued, Total	5.74M	-	-	-	-
Total Debt Issued	5.74M	-	-	-	-
Long-Term Debt Repaid, Total	-424K	-299K	-311K	-410K	-457K
Total Debt Repaid	-424K	-299K	-311K	-410K	-457K
Issuance of Common Stock	24.68M	20.24M	1.15M	258K	26.89M
Other Financing Activities, Total	-327K	-423K	-417K	-205K	-1.41M
Cash from Financing	29.67M	19.52M	425K	-357K	25.02M
Foreign Exchange Rate Adjustments	2K	20K	23K	11K	-49K
Net Change in Cash	20.67M	-20.43M	487K	-2.4M	17.34M
Supplemental Items
Cash Interest Paid	-	147K	126K	188K	144K
Levered Free Cash Flow	-3.09M	-	-	-5.9M	4.71M
Unlevered Free Cash Flow	-3M	-	-	-5.78M	4.8M
Change In Net Working Capital	118K	-	-	341K	-13.99M
Net Debt Issued / Repaid	5.31M	-299K	-311K	-410K	-457K

Fiscal Period: December	2021 (ILS)	2022 (ILS)	2023 (ILS)	2024 (ILS)	2025 (ILS)
Profitability
Return on Assets	-57.67	-	-	-41.48	-49.57
Return on Total Capital	-61.6	-	-	-45.04	-83.91
Return On Equity %	-112.59	-	-	-74.25	-220.42
Return on Common Equity	-112.59	-	-	-76.75	-220.76
Short Term Liquidity
Current Ratio	15.88	-	10.51	5.29	1.3
Quick Ratio	15.79	-	10.44	5.18	1.23
Operating Cash Flow to Current Liabilities	-4.63	-	-4.61	-4.92	-0.85
Average Days Payable Outstanding	-	-	-	902.89	408.26
Long Term Solvency
Total Debt/Equity	5.87	-	5.56	8.28	7.94
Total Debt / Total Capital	5.55	-	5.27	7.65	7.35
LT Debt/Equity	4.73	-	4.19	5.27	3.76
Long-Term Debt / Total Capital	4.47	-	3.97	4.87	3.48
Total Liabilities / Total Assets	9.24	-	11.26	17.36	63.83
EBIT / Interest Expense	-110.86	-85.62	-105.86	-85.71	-127.26
EBITDA / Interest Expense	-107.03	-80.1	-99.73	-80.45	-120.28
(EBITDA - Capex) / Interest Expense	-123.6	-83.01	-104.17	-81.74	-124.43
Total Debt / EBITDA	-0.1	-	-0.11	-0.08	-0.05
Net Debt / EBITDA	1.35	-	1.59	0.71	1.16
Total Debt / (EBITDA - Capex)	-0.09	-	-0.1	-0.08	-0.04
Net Debt / (EBITDA - Capex)	1.17	-	1.53	0.69	1.12
Growth Over Prior Year
Gross Profit, 1 Yr. Growth %	-	-	29.44	6.67	112.5
EBITDA, 1 Yr. Growth %	273.68	-23.34	17.14	9.26	14.19
EBITA, 1 Yr. Growth %	279.1	-21.7	16.91	9.51	13.73
EBIT, 1 Yr. Growth %	279.1	-21.7	16.91	9.51	13.73
Earnings From Cont. Operations, 1 Yr. Growth %	279.87	-23.6	10.77	12.66	78.55
Net Income, 1 Yr. Growth %	279.87	-23.6	10.77	12.66	78.55
Normalized Net Income, 1 Yr. Growth %	279.87	-23.6	10.64	12.79	78.55
Diluted EPS Before Extra, 1 Yr. Growth %	105.33	-49.32	-6.46	10.24	53.9
Net Property, Plant and Equip., 1 Yr. Growth %	144.19	-	-	-15.96	-15.46
Total Assets, 1 Yr. Growth %	386.99	-	-	-39.24	51.81
Tangible Book Value, 1 Yr. Growth %	6.53K	-	-	-48.11	-40.53
Common Equity, 1 Yr. Growth %	837.83	-	-	-43.42	-33.55
Cash From Operations, 1 Yr. Growth %	91.67	25.27	26.38	12.08	25.87
Capital Expenditures, 1 Yr. Growth %	2.48K	-82.18	43.93	-60.55	145.68
Levered Free Cash Flow, 1 Yr. Growth %	-	-	-	-	-175.08
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	-	-	-177.98
Compound Annual Growth Rate Over Two Years
Gross Profit, 2 Yr. CAGR %	-	-	-	17.5	50.55
EBITDA, 2 Yr. CAGR %	-	69.25	-5.24	13.14	11.7
EBITA, 2 Yr. CAGR %	229.17	72.29	-4.32	13.15	11.6
EBIT, 2 Yr. CAGR %	229.17	72.29	-4.32	13.15	11.6
Earnings From Cont. Operations, 2 Yr. CAGR %	210.37	70.36	-8	11.71	41.83
Net Income, 2 Yr. CAGR %	210.37	70.36	-8	11.71	41.83
Normalized Net Income, 2 Yr. CAGR %	229.41	70.36	-8.06	11.71	41.91
Diluted EPS Before Extra, 2 Yr. CAGR %	124.97	2.01	-31.15	1.55	30.25
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-1.2	-	-15.71
Total Assets, 2 Yr. CAGR %	-	-	2.23	-	-3.96
Tangible Book Value, 2 Yr. CAGR %	-	-	0.84	-	-44.45
Common Equity, 2 Yr. CAGR %	-	-	1.09	-	-38.68
Cash From Operations, 2 Yr. CAGR %	278.65	54.95	25.82	19.02	18.78
Capital Expenditures, 2 Yr. CAGR %	1.23K	114.53	-49.36	-24.65	-1.55
Compound Annual Growth Rate Over Three Years
Gross Profit, 3 Yr. CAGR %	-	-	-	-	43.16
EBITDA, 3 Yr. CAGR %	-	-	49.71	-0.63	13.49
EBITA, 3 Yr. CAGR %	-	103.95	51.4	0.08	13.34
EBIT, 3 Yr. CAGR %	-	103.95	51.4	0.08	13.34
Earnings From Cont. Operations, 3 Yr. CAGR %	-	94.52	47.59	-1.57	30.61
Net Income, 3 Yr. CAGR %	-	94.52	47.59	-1.57	30.61
Normalized Net Income, 3 Yr. CAGR %	-	102.39	47.53	-1.57	30.61
Diluted EPS Before Extra, 3 Yr. CAGR %	-	36.88	-0.9	-19.45	16.64
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	33.59	-6.39	-
Total Assets, 3 Yr. CAGR %	-	-	72.01	-14.05	-
Tangible Book Value, 3 Yr. CAGR %	-	-	306.94	-19.19	-
Common Equity, 3 Yr. CAGR %	-	-	112.41	-16.69	-
Cash From Operations, 3 Yr. CAGR %	-	161.88	44.77	21.07	21.26
Capital Expenditures, 3 Yr. CAGR %	-	216.5	87.8	-53.4	11.73
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	24	-
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	24.4	-
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	-	33.16
EBITA, 5 Yr. CAGR %	-	-	-	61.13	34.01
EBIT, 5 Yr. CAGR %	-	-	-	61.13	34.01
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	55.82	45.26
Net Income, 5 Yr. CAGR %	-	-	-	55.82	45.26
Normalized Net Income, 5 Yr. CAGR %	-	-	-	59.57	45.26
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	21.47	10.55
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	11.11
Total Assets, 5 Yr. CAGR %	-	-	-	-	36.24
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	83.48
Common Equity, 5 Yr. CAGR %	-	-	-	-	29.22
Cash From Operations, 5 Yr. CAGR %	-	-	-	91.03	33.75
Capital Expenditures, 5 Yr. CAGR %	-	-	-	78.26	45.04